P300/CBP-HAT-INHIBITOREN

European patent · EP3752250 · Deleted

Register entry

Publication number
EP3752250
Application number
EP19708731
Kind
European patent with effect for Switzerland and Liechtenstein
Status
Deleted
Specification
Granted
Filed
Feb 15, 2019
Published
Dec 23, 2020
Granted
Aug 3, 2022
Deleted
Sep 23, 2023
Reason
Annual fee unpaid
IPC classes
A61P 11/00 (2006.01)
A61P 3/00 (2006.01)
A61P 9/00 (2006.01)
A61P 29/00 (2006.01)
A61P 35/00 (2006.01)
A61P 31/12 (2006.01)
C07D 403/12 (2006.01)
A61K 31/337 (2006.01)
A61K 31/38 (2006.01)
A61K 31/397 (2006.01)
A61K 31/4025 (2006.01)
A61K 31/404 (2006.01)
A61K 31/4155 (2006.01)
A61K 31/4162 (2006.01)
A61K 31/4184 (2006.01)
A61K 31/4188 (2006.01)
A61K 31/4192 (2006.01)
A61K 31/4196 (2006.01)
A61K 31/4355 (2006.01)
A61K 31/454 (2006.01)
Priority
US 201862631594 P 16.02.2018
US 201862758867 P 12.11.2018
PCT application
PCT/US2019/018150 15.02.2019
PCT publication
WO2019/161157 22.08.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 23, 2023

    Deleted, fee unpaid

    Published in Swissreg on 23.09.2023

  2. Jun 14, 2023

    Change

    Published in Swissreg on 14.06.2023

  3. Aug 3, 2022

    Granted

    Published in Swissreg on 03.08.2022

Parties

Holder

Constellation Pharmaceuticals, Inc.

215 First Street, Suite 200, Cambridge, MA 02142, US

Inventor

WILSON, Jonathan, E.

Arlington, MA 02474, US

LEVELL, Julian, R.

Arlington, MA 02474, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.